Test Price
2,800 AED✅ Home Collection Available
MYPN Gene Dilated Cardiomyopathy Type 1KK Genetic Test in UAE | DNA Labs UAE
Executive Summary & Core Metrics
Precision genetic screening for MYPN-related dilated cardiomyopathy, enhanced by clinical oversight and regulatory compliance.
- Precision Promise: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Workflow (Cert: INT/EGQ/2509DA/3139).
- Premium Home Collection: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across Dubai, Abu Dhabi, and all Emirates.
- Post-Test Clinical Guidance: Dedicated telephonic consultation with our Consultant Medical Geneticist to provide context and actionable next steps.
- Insurance & Billing: Direct insurance verification and pre-approval via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This high-resolution genetic test sequences the entire coding region of the MYPN gene using Next-Generation Sequencing (NGS) to identify pathogenic variants responsible for Dilated Cardiomyopathy Type 1KK. Results empower precise risk stratification, early intervention, and cascade family screening.
| Feature | DNA Labs UAE MYPN NGS Test | Standard Sanger Sequencing |
|---|---|---|
| Diagnostic Sensitivity | >99.9% (full exon coverage) | ~95% (single-exon bias) |
| Methodology | NGS (Illumina NovaSeq) + LC‑MS/MS confirmation | Sanger Sequencing |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Variant Detection | SNVs, Indels, CNVs | SNVs, small Indels only |
Physician Insight & Safety Protocols
“A pathogenic MYPN variant indicates a strong predisposition to dilated cardiomyopathy, but it must be interpreted within the full clinical context. We strongly advise integrating these results with echocardiography, ECG, and a three-generation family history. Cascade screening for all first-degree relatives is a critical preventive measure.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety Advisory
Do not discontinue or modify any prescribed cardiac medication (beta-blockers, ACE inhibitors, etc.) based solely on this genetic result. Always consult your treating cardiologist for medication management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Asymptomatic individuals with no personal or family history of cardiomyopathy, unexplained heart failure, or sudden cardiac death before age 50 may not qualify for insurance coverage.
- Exclusion: Patients who have not undergone pre-test genetic counselling as required by UAE regulatory guidelines.
- Red Flag: If you experience exertional chest pain, syncope (fainting), or palpitations, seek emergency medical evaluation immediately—do not wait for genetic results.
Patient FAQ & Clinical Guidance
1. What is the MYPN Gene Dilated Cardiomyopathy Type 1KK Genetic Test?
This genetic test analyzes the MYPN gene through comprehensive NGS to identify pathogenic variants responsible for dilated cardiomyopathy type 1KK, enabling accurate diagnosis and management. It is the only DHA-aligned test that integrates LC‑MS/MS confirmation for variant validity.
2. How accurate is this test compared to other genetic cardiac panels?
Our NGS‑based MYPN test achieves >99.9% analytical sensitivity with full exon coverage, surpassing traditional Sanger sequencing and most limited panels in detecting both point mutations and copy‑number variations.
3. Is home blood collection available in Dubai and Abu Dhabi for this test?
Yes, we provide ISO‑certified cold‑chain home collection by DHA‑licensed phlebotomists daily from 8:00 AM to 11:00 PM across all Emirates, including Dubai and Abu Dhabi, with insurance pre‑verification via WhatsApp.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to the highest standards of data protection and healthcare regulations in the United Arab Emirates. Patient data is handled in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
All genetic counselling and testing are performed under DHA Facility License 1143. ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | MYPN Gene Dilated Cardiomyopathy Type 1KK Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or Buccal Swab |
| Methodology Used | Next-Generation Sequencing (NGS) + LC-MS/MS Confirmation |
| ICD-10-CM Code | I42.0, Z15.89, Z82.41 |
| LOINC Code | 101943-6 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians